NZ505063A - Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions - Google Patents

Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions

Info

Publication number
NZ505063A
NZ505063A NZ505063A NZ50506398A NZ505063A NZ 505063 A NZ505063 A NZ 505063A NZ 505063 A NZ505063 A NZ 505063A NZ 50506398 A NZ50506398 A NZ 50506398A NZ 505063 A NZ505063 A NZ 505063A
Authority
NZ
New Zealand
Prior art keywords
ptx3
long pentraxin
pharmaceutical use
pentraxin ptx3
treating tumour
Prior art date
Application number
NZ505063A
Other languages
English (en)
Inventor
Barbara Bottazzi
Martino Introna
Alberto Mantovani
Annunciata Vecchi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of NZ505063A publication Critical patent/NZ505063A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ505063A 1997-12-19 1998-12-16 Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions NZ505063A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000796A IT1298487B1 (it) 1997-12-19 1997-12-19 Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
PCT/IT1998/000364 WO1999032516A2 (en) 1997-12-19 1998-12-16 Pharmaceutical compositions containing the long pentraxin ptx3

Publications (1)

Publication Number Publication Date
NZ505063A true NZ505063A (en) 2002-12-20

Family

ID=11405409

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ505063A NZ505063A (en) 1997-12-19 1998-12-16 Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions

Country Status (13)

Country Link
US (1) US8003109B2 (https=)
EP (1) EP1034185B1 (https=)
JP (1) JP4173633B2 (https=)
KR (1) KR100560085B1 (https=)
AT (1) ATE295853T1 (https=)
AU (1) AU756974B2 (https=)
CA (1) CA2315277C (https=)
DE (1) DE69830251T2 (https=)
ES (1) ES2242309T3 (https=)
IT (1) IT1298487B1 (https=)
NZ (1) NZ505063A (https=)
PT (1) PT1034185E (https=)
WO (1) WO1999032516A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20040198655A1 (en) * 2001-08-03 2004-10-07 Alberto Mantovani Use of long pentraxin ptx3 for treating female infertility
US7041648B2 (en) 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
US8076300B2 (en) * 2006-01-24 2011-12-13 Tecnogen S.P.A. FGF2-binding peptides and uses thereof
EP1832295A1 (en) 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
RS52377B (sr) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
WO2009095403A1 (en) * 2008-01-29 2009-08-06 Tecnogen S.P.A. Expression system and uses thereof for the production of human long pentraxin 3
ES2432242T3 (es) 2009-07-29 2013-12-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Sistema mejorado de expresión de pentraxina 3 larga humana y sus usos
KR101305515B1 (ko) 2011-06-10 2013-09-06 경북대학교 산학협력단 펜트락신 3 단백질의 파킨슨 질환 진단 용도
WO2013191280A1 (ja) * 2012-06-22 2013-12-27 国立大学法人 東京大学 全身性炎症反応症候群の治療又は予防剤
TWI528969B (zh) 2013-06-07 2016-04-11 國立成功大學 胺基酸序列用於製備抑制ｐｔｘ３治療鼻咽癌之醫藥組合物之用途
TWI531375B (zh) 2015-05-29 2016-05-01 國立成功大學 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物
CN105132459B (zh) * 2015-09-14 2019-01-29 武汉市星熠艾克生物医药有限责任公司 人类ptx3重组蛋白的制备方法及应用
EP4103592A4 (en) * 2020-02-12 2024-01-10 BioTissue Holdings Inc. METHODS OF DESTRUCTING OR INHIBITING THE GROWTH OF CANCER CELLS
US20230227511A1 (en) * 2020-05-14 2023-07-20 Nippon Medical School Foundation Therapeutic or preventive agent for infectious disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
EP0571442A4 (en) * 1991-01-14 1995-05-03 Univ New York PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
IT1254687B (it) * 1992-04-14 1995-09-28 Italfarmaco Spa Gene inducibile da citochine
US6210941B1 (en) 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US7041648B2 (en) 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
US20040198655A1 (en) 2001-08-03 2004-10-07 Alberto Mantovani Use of long pentraxin ptx3 for treating female infertility
US20040137544A1 (en) 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
JP2006524704A (ja) 2003-04-23 2006-11-02 サイクローン・ファーマシューティカルズ・インコーポレイテッド アルファチモシンペプチドによる呼吸器ウイルス感染の治療または予防
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (en) 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
RS52377B (sr) 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom

Also Published As

Publication number Publication date
ATE295853T1 (de) 2005-06-15
WO1999032516A3 (en) 1999-10-28
US8003109B2 (en) 2011-08-23
JP2002503642A (ja) 2002-02-05
PT1034185E (pt) 2005-07-29
KR100560085B1 (ko) 2006-03-13
ES2242309T3 (es) 2005-11-01
AU1782999A (en) 1999-07-12
DE69830251T2 (de) 2005-10-27
EP1034185A2 (en) 2000-09-13
CA2315277C (en) 2010-02-23
DE69830251D1 (de) 2005-06-23
CA2315277A1 (en) 1999-07-01
KR20010033297A (ko) 2001-04-25
US20080015153A1 (en) 2008-01-17
JP4173633B2 (ja) 2008-10-29
AU756974B2 (en) 2003-01-30
ITRM970796A1 (it) 1999-06-19
EP1034185B1 (en) 2005-05-18
WO1999032516A2 (en) 1999-07-01
IT1298487B1 (it) 2000-01-10

Similar Documents

Publication Publication Date Title
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
DE69534618D1 (de) Verfahren zur herstellung rekombinanter adeno-associated viren (aav) und deren verwendung
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
IL114904A0 (en) Adenovirus comprising a gene encoding glutathione peroxidase
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
AP2000001999A0 (en) Gene therapy method.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
NO960325L (no) Tryptaseinhibitor
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
UA70909C2 (uk) Рекомбінантний аденовірусний вектор, фармацевтична композиція, що його містить, та набір для зменшення проліферації пухлинних клітин
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
ZA887950B (en) Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions
NO941982L (no) Fremstilling av proteiner ved anvendelse av 7B2 protein
ATE309354T1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired